share_log

Brookline Capital Initiates Coverage On IBio With Buy Rating, Announces Price Target of $3.6

Benzinga ·  Jul 23 00:20  · Ratings

Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $3.6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment